The financing provides a cash infusion but at a deeply discounted price ($0.14 vs. current market) with massive potential dilution from warrants. The second tranche and FDA approval warrants are binary events tied to seralutinib's NDA acceptance and approval. Monitor the proxy filing and special meeting timeline for stockholder approval, and the NDA acceptance milestone by December 31, 2026. Given the company's pre-revenue status and poor historical returns, this is a high-risk, catalyst-dependent story.
Price Chart
Executive Summary
Gossamer Bio entered into a securities purchase agreement for a two-tranche private placement of pre-funded warrants and FDA approval warrants, raising an initial undisclosed amount at $0.1399 per warrant (representing a $0.14 per share common stock price) and a second tranche contingent on NDA acceptance for seralutinib. The deal includes a potential $100M FDA approval warrant exercise, a lock-up on insiders, and a commitment to seek stockholder approval. This financing provides near-term cash runway but creates significant dilution and a complex capital structure tied to binary regulatory milestones, which is bearish given the company's pre-revenue status and poor historical stock performance.
Key Facts
- Initial closing of pre-funded warrants at $0.1399 per warrant (implied common stock price of $0.14), with a second closing contingent on FDA acceptance of the NDA for seralutinib.
- Second closing includes additional pre-funded warrants and FDA approval warrants exercisable at $0.187 per share for up to $100M in aggregate exercise price.
- Stockholder approval required for conversion to common stock; lock-up agreements from directors and officers until 90 days after NDA acceptance or abandonment.
- Company must file a proxy statement within 10 days of initial closing and hold a special meeting to obtain stockholder approval.
Financial Impact
Initial raise of undisclosed amount at $0.14/share implied price; potential second tranche of undisclosed size; up to $100M in FDA approval warrant exercise proceeds contingent on FDA approval.
Risk Factors
- Dilution from pre-funded warrants and FDA approval warrants could be substantial if exercised.
- Second closing contingent on NDA acceptance by December 31, 2026 — failure would eliminate that tranche.
- Stockholder approval required for conversion to common stock; failure could complicate capital structure.
- Pre-revenue biotech with binary regulatory risk on seralutinib NDA.
- Historical poor stock performance suggests market skepticism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001728117-26-000077 |
| Exhibit: ex42.htm | 0001728117-26-000077 |
| Exhibit: ex41.htm | 0001728117-26-000077 |
| Exhibit: ex43.htm | 0001728117-26-000077 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | SC 13D/A | $9.31 | awaiting T+20 | — | $9.15 (+1.72%) |
Sep 28, 2026 28d ago | SC 13D/A | $11.58 | awaiting T+20 | — | $9.15 (+20.98%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.69 $9.58 | ▼ −18.05% | ▼ −17.49% | $9.15 (−21.73%) |
Sep 16, 2026 5w ago | 8-K | $11.94 $8.89 | ▼ −25.54% | ▼ −26.75% | $9.15 (−23.37%) |
Sep 11, 2026 6w ago | 8-K | $10.73 $9.31 | ▲ +13.23% | ▲ +15.10% | $9.15 (+14.73%) |
Sep 9, 2026 6w ago | 8-K | $0.1597 $0.1273 | ▼ −20.32% | ▼ −22.26% | $9.15 (+5629.49%) |
Aug 21, 2026 9w ago | 8-K | $0.1547 $0.1410 | ▲ +8.86% | ▲ +9.87% | $9.15 (−5814.67%) |
Aug 13, 2026 10w ago | 8-K | $0.1542 $0.1337 | ▼ −13.26% | ▼ −11.27% | $9.15 (+5833.85%) |
Jul 1, 2026 16w ago | 8-K | $0.1677 $0.1783 | ▼ −6.32% | ▼ −6.87% | $9.15 (−5356.17%) |
Jun 17, 2026 18w ago | 8-K | $0.1790 $0.1701 | ▲ +4.97% | ▲ +5.29% | $9.15 (−5011.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers